<a href="https://www.fiercebiotech.com/biotech/new-heights-newlimit-anti-aging-biotech-nabs-435m-rejuvenate-old-cells" hreflang="en">New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells</a>
Anti-aging biotech startup NewLimit has raised $435 million in funding after unexpectedly advancing its lead drug candidate for rejuvenating liver cells, aiming to enter phase 1 trials next year. The company plans to expand its research to other cell types and address broader health issues related to aging, positioning itself as a serious player in the longevity biotech field.
NewLimit's rapid development of a clinic-ready anti-aging candidate in liver cell rejuvenation, backed by a significant $435M funding round, highlights the potential for AI and advanced screening platforms to accelerate drug discovery in biotech. The company's approach, focusing on transcription factor combinations, not only aims to tackle aging-related diseases but also signals a broader application of their technology to other cell types like endothelial and T cells. This presents a compelling investment opportunity in healthtech and biotech for stakeholders interested in cutting-edge, scientifically rigorous approaches to longevity and chronic disease treatment.